{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"4.01"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"5.75"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"6.27"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"6.4","value":"4.55"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"5.10"},{"groupId":"OG005","lowerLimit":"3.5","upperLimit":"4.6","value":"4.07"},{"groupId":"OG006","lowerLimit":"5.2","upperLimit":"10.3","value":"6.48"},{"groupId":"OG007","lowerLimit":"2.9","upperLimit":"9.3","value":"3.96"},{"groupId":"OG008","lowerLimit":"1.4","upperLimit":"8.1","value":"5.55"},{"groupId":"OG009","lowerLimit":"3.3","upperLimit":"6.3","value":"4.57"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"4.15"},{"groupId":"OG011","lowerLimit":"4.1","upperLimit":"7.4","value":"4.75"},{"groupId":"OG012","lowerLimit":"3.0","upperLimit":"5.8","value":"4.06"},{"groupId":"OG013","lowerLimit":"1.9","upperLimit":"9.7","value":"5.66"},{"groupId":"OG014","lowerLimit":"4.7","upperLimit":"7.5","value":"6.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"5"}],"units":"Participants"}],"description":"Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.","dispersionType":"Full Range","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"MEDIAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: Terminal Half Life (T1/2) of GSK525762 Following Single Dose Administration","type":"SECONDARY","unitOfMeasure":"Hour"}